Pacira BioSciences, Inc. Common Stock (PCRX)
PHARMACEUTICAL PREPARATIONS
Pacira BioSciences, Inc. Common Stock (PCRX) is listed on Nasdaq, where it has traded since February 3, 2011.
- Listed On
- Nasdaq
- Listed Since
- February 3, 2011
- Employees
- 829
- Market Cap
- $1.0B
About Pacira BioSciences, Inc. Common Stock
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 244 institutions reported holding PCRX, with 43.5 million shares worth $1.1 billion in aggregate. The largest reported holder was BlackRock, with 6.7 million shares worth $170.1 million. Of the 5 largest holders listed below, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| BlackRock | 6,705,809 | $170M | Reduced 0.44% |
| Vanguard | 4,478,833 | $114M | Reduced 4.18% |
| Doma Perpetual Capital Management | 2,777,794 | $70M | Unchanged |
| Dimensional Fund Advisors | 2,103,245 | $53M | Added 2.07% |
| State Street | 2,059,977 | $52M | Added 7.31% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is PCRX?
Pacira BioSciences, Inc. Common Stock (PCRX) is listed on Nasdaq, where it has traded since February 3, 2011.
Who are the largest institutional holders of PCRX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of PCRX were BlackRock, Vanguard and Doma Perpetual Capital Management.
How many institutions own PCRX?
244 institutions reported a position in PCRX for the quarter ended June 30, 2026, worth $1.1 billion in total.
Did institutions buy or sell PCRX last quarter?
Of the 5 largest reported holders, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for PCRX.
Every reported institutional holder, plus insider and congressional trades in PCRX, on SentiSense.